Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide

Hypertension
K B BrosnihanC M Ferrario

Abstract

Angiotensin-(1-7) [Ang-(1-7)] was recently recognized to have novel biological functions that are distinct from those of Ang II. In these studies, we determined the vasoactive effects of Ang-(1-7) together with the endothelium-dependent mediator(s) of these responses in canine coronary arteries. Isometric tension was measured in intact canine coronary artery rings suspended in organ chambers perfused with 95% O2/5% CO2 at 37 degrees C. Ang-(1-7) caused significant concentration-dependent vascular relaxation (2.73 +/- 0.58 micromol/L, EC50) of rings precontracted with the thromboxane A2 analogue U46,619. Pretreatment with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine (1 mol/L) abolished the vasodilator response to Ang-(1-7), whereas treatment with the cyclooxygenase inhibitor indomethacin (10 micromol/L) was without effect. The vasodilator response produced by Ang-(1-7) was blocked by 75% with the bradykinin B2 receptor antagonist Hoe 140 (1 micromol/L) or by 80% with the nonselective Ang II antagonist [Sar1,Thr8]-Ang II (1 micromol/L). In contrast, the selective AT1 or AT2 Ang II antagonists CV 11974 (1 micromol/L), and PD 123319 (1 micromol/L), respectively, were ineffective in inhibiting the Ang-(1-7)-elicited...Continue Reading

References

Apr 1, 1977·Physiological Reviews·M J Peach
Feb 1, 1992·Hypertension·R A SantosC M Ferrario
Mar 1, 1992·The American Journal of Physiology·M FélétouB Teisseire
May 1, 1991·The American Journal of Physiology·G SaccomaniR L Shoemaker
Nov 1, 1991·Hypertension·C M FerrarioE A Tallant
Feb 1, 1990·Hypertension·R A SantosC M Ferrario
Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M T SchiavoneC M Ferrario
Jul 1, 1995·The American Journal of Physiology·I F BenterD I Diz
Mar 30, 1993·European Journal of Pharmacology·S Y OseiP J Kadowitz
Sep 1, 1994·Current Opinion in Cardiology·C M Ferrario, M C Chappell
Jul 1, 1993·Peptides·I F BenterC M Ferrario
Nov 1, 1993·Kidney International·S Andreatta-van LeyenJ G Douglas
Sep 1, 1993·Peptides·K KoharaC M Ferrario
Oct 1, 1993·Hypertension·D J CampbellA M Duncan
Feb 1, 1993·Hypertension·D J CampbellA M Duncan

❮ Previous
Next ❯

Citations

Apr 26, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jasmina VaragicCarlos M Ferrario
Mar 11, 2008·Cardiovascular Drugs and Therapy·Sharmalar Rajendran, Yuliy Y Chirkov
Jul 18, 2006·Biochemical and Biophysical Research Communications·Elzbieta RebasAgnieszka Lachowicz
Jul 13, 2005·Progress in Biophysics and Molecular Biology·Shant Der SarkissianMohan K Raizada
Apr 15, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Frédérique RyckwaertPierre Foëx
Dec 22, 1998·The American Journal of Cardiology·K B Brosnihan
Sep 30, 1996·The American Journal of Medicine·D S HanesJ R Sowers
Jul 26, 2002·Regulatory Peptides·R D P MachadoS P Andrade
May 7, 2003·Peptides·Liomar A A NevesK Bridget Brosnihan
Jul 17, 1999·Trends in Endocrinology and Metabolism : TEM·E G ErdösB M Marcic
Apr 5, 2003·The International Journal of Biochemistry & Cell Biology·Beril TomA H Jan Danser
May 23, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaru Iwai, Masatsugu Horiuchi
Nov 30, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shinji TakaiMizuo Miyazaki
Feb 24, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Satu LuhtalaHeikki Vapaatalo
Dec 5, 1997·Journal of Cardiovascular Pharmacology·Y le Tran, C Forster
Oct 8, 1999·Journal of Cardiovascular Pharmacology·G BerkenboomJ Fontaine
Apr 13, 2001·Journal of Cardiovascular Pharmacology·M A ClarkD I Diz
Jan 28, 2003·Journal of Cardiovascular Pharmacology·Michelle A ClarkDebra I Diz
Apr 9, 2004·Journal of Cardiovascular Pharmacology·Luciana Gonçalves MaiaRobson Augusto Souza dos Santos
Sep 15, 2005·Journal of Cardiovascular Pharmacology·Sharmalar RajendranJohn D Horowitz
Aug 19, 2007·Journal of Cardiovascular Pharmacology·Mohan K Raizada, Anderson J Ferreira
Feb 13, 2007·Current Opinion in Nephrology and Hypertension·Robson A S Santos, Anderson J Ferreira
Mar 1, 2008·Clinical and Experimental Pharmacology & Physiology·A KoitkaC Tikellis
Feb 7, 2009·Clinical and Experimental Pharmacology & Physiology·Wing Tak Wong, Yu Huang
Jun 21, 2008·Acta Pharmacologica Sinica·Ying ShaoLi-min Lu
May 25, 2002·Canadian Journal of Physiology and Pharmacology·Anthony J TurnerNigel M Hooper

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.